Immucor Closes BioArray Acquisition

NORCROSS, Ga., Aug. 5 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq:
BLUD), a global leader in providing automated instrument-reagent systems to
the blood transfusion industry, announced today that it has closed its
previously-announced acquisition of BioArray Solutions Ltd.
Gioacchino De Chirico, President & CEO of Immucor, said, "We are pleased
to have completed this acquisition, which we believe will enable us to provide
innovative molecular diagnostic solutions for blood transfusions to enhance
patient outcomes."
Immucor expects to provide more information about the BioArray acquisition
on its investors conference call in October to review the results of its first
fiscal quarter.
Founded in 1982, Immucor manufactures and sells a complete line of
reagents and systems used by hospitals, reference laboratories and donor
centers to detect and identify certain properties of the cell and serum
components of blood prior to transfusion. Immucor markets a complete family of
automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at
http://www.immucor.com .
Statements contained in this press release that are not statements of
historical fact are "forward-looking statements" as that term is defined under
federal securities laws, including, without limitation, all statements
concerning Immucor's expectations, beliefs, intentions or strategies for the
future. Factors related to the BioArray acquisition that could adversely
affect the Company's results include but are not limited to: the ability of
the Company to successfully develop an automated platform for BioArray's
transfusion genotyping system, and the cost to do so; the ability of the
Company to gain FDA clearance for that automated platform; the acceptance of
BioArray technology in transfusion and transplantation markets; and the cost
to successfully market and sell products incorporating BioArray technology.
Further risks concerning the Company's business are detailed in the Company's
filings with the Securities and Exchange Commission. Investors are cautioned
not to place undue reliance on any forward-looking statements. Immucor
assumes no obligation to update any forward-looking statements.
SOURCE Immucor, Inc.

Rick Flynt, Immucor, Inc., +1-770-441-2051